Clinical Research Directory

Inclusion Criteria: * Small cell lung cancer confirmed by pathology, with brain metastases diagnosed either at initial presentation or during treatment, and measurable disease according to RECIST criteria. * The expected survival time is more than 3 months. * Intracranial metastases ≤10. * Adequate organ and bone marrow function. * Women of childbearing potential must agree to use effective contraception during the study and for 6 months after its completion. Exclusion Criteria: * Patients who have used antiangiogenic drugs within the previous 1 month. * Non-small cell lung cancer (including combined small cell carcinoma). * Small cell lung cancer with hilar invasion or hemoptysis. * Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage. * An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment. * Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications. * Patients with life-threatening conditions of other severe and/or uncontrolled diseases. * History of prior brain radiotherapy.